The Roche Tecentriq/Avastin combination improves the overall survival of hepatocellular carcinoma

Compile | According to the results of a trial of Atezolizumab and Bevacizumab combined therapies published by Roche, the latest results show that the combination of Tecentriq/Avastin can improve the overall survival (OS) of patients with hepatocellular carcinoma (HCC).
The updated OS data comes from a global Phase 3, Multicenter, Open Phase III PHASE III IMbrave150 trial that assessed the efficacy of Tecentriq in association with the current standard treatment, Sorafenib, in patients with hepatocellular carcinoma who had not yet received systemic treatment.
15.6 months after the mid-level follow-up, the latest analysis of the results of the IMbrave150 trial showed that Tecentriq and Avastin reduced the risk of death by 34 per cent, with a mid-OS of 19.2 months and Sorafenib of 13.4 months.
note that the median total survival of the Chinese sub-group subjects in the trial reached 24.0 months, which was better than the 11.4 months of the previous standard scheme (HR-0.53; 95% CI: 0.35-0.80）。
analysis of the Imbrave150 trial showed that tecentriq and Avastin combined therapy reduced the risk of death (OS) by 42 per cent after 8.6 months of follow-up.
In response, Levi Garraway, Roche's chief medical officer and head of global product development, said the results showed that Tecentriq and Avastin's Phase III trial results showed that patients reached the longest survival rate in non-removable hepatocellular carcinoma first-line treatment, a combination that has now been approved by regulators in more than 60 countries and regions around the world, meaning the combination has helped make significant progress in treating this malignant tumor.
hepatocellular carcinoma is a malignant tumor that currently has limited treatment options, and more than 815,000 people worldwide are diagnosed with the cancer each year, most of them in Asia and almost half in China.
liver cell carcinoma is mainly due to chronic hepatitis B, hepatitis C or alcohol consumption and develops in patients with cirrhosis, and patients are often found to be in the cancer stage.
Tecentriq/Avastin combination has been approved in many countries and regions, including the United States, Japan and the European Union, to treat patients with hepatocellular carcinoma that cannot be removed.
October 2020, tecentriq and Avastin immunization joint program was officially approved in China, and has been listed as recommended therapy by several authoritative clinical guidelines in China, proving the breakthrough of tecentriq and Avastin combination therapy.
test results show that the latest OS, PFS, and ORR results from Tecentriq and Avastin combination therapies are consistent with the initial analysis and support the combination therapy for the treatment of patients with hepatocellular carcinoma.
the safety of Tecentriq and Avastin combination therapies is consistent with the known safety of each drug, and no new adverse events occur.